Baker McKenzie’s Corporate team has advised Sofinnova Partners and Asabys Partners on a 12 million euros investment round in Barcelona-based biotech Nuage Therapeutics. The company plans to use the proceeds of the deal to initiate animal testing of the drugs it is investigating against resistant prostate cancer, the second leading cause of cancer-related death in men.
Carlos Martín (Team Leader) and Isabel Rodríguez (Corporate/M&A Junior Associate) have formed the advisory team to Sofinnova Partners and Asabys Partners, two of the largest venture capital managers in Spain and Europe.
Sofinnova is a leading pan-European venture capital fund, with offices in Paris, London and Milan, which has been investing in life sciences companies for 50 years and currently has 2.5 billion in assets under management. Asabys stands out as one of the leading healthcare investment firms in Spain and manages 217 million in assets.